Ospraie Ag Science LLC

SEC source: 0001213900-22-039487 · ownership.xml · nonDerivative · entry 1

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks)

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: Disposed of pursuant to the Agreement and Plan of Merger dated March 16, 2022 by and among the Issuer, Bioceres Crop Solutions Corp. and BCS Merger Sub, Inc. (the "Merger Agreement") in exchange for 6,233,590 ordinary shares of Bioceres Crop Solutions Corp. having a market value of $9.44 per share at closing on the effective date of the merger.

F2 · ownership.direct: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie Ag Science LLC ("Ospraie LLC") and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. OAS MM, LLC may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie LLC. Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and sole managing member of OAS MM, LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-21-048765 · doc4.xml · derivative · entry 2

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,553,583 shares

Expires 2021-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On December 15, 2021, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 3,553,583 shares of Issuer Common Stock underlying such warrants.

F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F3 · kind: (Continued from Footnot 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On December 15, 2021, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 3,553,583 shares of Issuer Common Stock underlying such warrants.

F2 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F3 · price: (Continued from Footnot 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-21-048765 · doc4.xml · nonDerivative · entry 1

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,836,258

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On December 15, 2021, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 3,553,583 shares of Issuer Common Stock underlying such warrants.

F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F3 · kind: (Continued from Footnot 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-21-011876 · doc4.xml · derivative · entry 2

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,264,299 shares

Expires 2021-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On March 15, 2021, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 4,264,299 shares of Issuer Common Stock underlying such warrants.

F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F3 · kind: (continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On March 15, 2021, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 4,264,299 shares of Issuer Common Stock underlying such warrants.

F2 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F3 · price: (continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-21-011876 · doc4.xml · nonDerivative · entry 1

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,282,675

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On March 15, 2021, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 4,264,299 shares of Issuer Common Stock underlying such warrants.

F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F3 · kind: (continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-20-034269 · doc4.xml · derivative · entry 2

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,476,221 shares

Expires 2020-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On December 15, 2020, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 9,476,221 shares of Issuer Common Stock underlying such warrants.

F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F3 · kind: (Continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On December 15, 2020, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 9,476,221 shares of Issuer Common Stock underlying such warrants.

F2 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F3 · price: (Continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-20-034269 · doc4.xml · nonDerivative · entry 1

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,018,376

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On December 15, 2020, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 9,476,221 shares of Issuer Common Stock underlying such warrants.

F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F3 · kind: (Continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-20-028006 · doc4.xml · derivative · entry 2

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,974,213 shares

Expires 2020-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On September 15, 2020, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 1,974,213 shares of Issuer Common Stock underlying such warrants.

F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F3 · kind: (Continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On September 15, 2020, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 1,974,213 shares of Issuer Common Stock underlying such warrants.

F2 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F3 · price: (Continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-20-028006 · doc4.xml · nonDerivative · entry 1

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,542,155

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On September 15, 2020, Ospraie Ag Science LLC ("Ospraie LLC") exercised warrants to purchase Common Stock of Marrone Bio Innovations, Inc. (the "Issuer") and purchased the 1,974,213 shares of Issuer Common Stock underlying such warrants.

F2 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F3 · kind: (Continued from footnote 2) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 12

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,467,766 shares

Expires 2020-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-20-011723 · doc4.xml · nonDerivative · entry 1

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,567,942

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 11

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,553,583

Underlying: Common Stock · 3,553,583 shares

Expires 2021-12-15

F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 10

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,264,299

Underlying: Common Stock · 4,264,299 shares

Expires 2021-03-15

F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 9

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,476,221

Underlying: Common Stock · 9,476,221 shares

Expires 2020-12-15

F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 8

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,974,213

Underlying: Common Stock · 1,974,213 shares

Expires 2020-09-15

F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 7

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,467,766

Underlying: Common Stock · 2,467,766 shares

Expires 2020-05-01

F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 6

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,027,325 shares

Expires 2023-01-01

F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F5 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement pursuant to which the Issuer had a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right was in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants (the "Reorganization Agreement Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such Reorganization Warrants were first exercisable 180 days after issuance, had a term expiring on January 1, 2023 and had an exercise price of $1.75 per share.

SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 5

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,675,771 shares

Expires 2023-01-01

F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F5 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement pursuant to which the Issuer had a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right was in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants (the "Reorganization Agreement Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such Reorganization Warrants were first exercisable 180 days after issuance, had a term expiring on January 1, 2023 and had an exercise price of $1.75 per share.

SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 4

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,351,542 shares

Expires 2023-01-01

F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F5 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement pursuant to which the Issuer had a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right was in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants (the "Reorganization Agreement Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such Reorganization Warrants were first exercisable 180 days after issuance, had a term expiring on January 1, 2023 and had an exercise price of $1.75 per share.

SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 3

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,378,871 shares

Expires 2023-01-01

F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F5 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement pursuant to which the Issuer had a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right was in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants (the "Reorganization Agreement Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such Reorganization Warrants were first exercisable 180 days after issuance, had a term expiring on January 1, 2023 and had an exercise price of $1.75 per share.

SEC source: 0000899243-20-011723 · doc4.xml · derivative · entry 2

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · See Remarks

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · See Remarks

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · See Remarks

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · See Remarks

Anderson Dwight · CIK 0001392202 · Director · 10% owner · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,233,158 shares

Expires 2021-12-31

F1 · kind: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · kind: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · kind: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · kind: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F1 · price: On April 29, 2020, Marrone Bio Innovations, Inc. (the "Issuer") entered into a Warrant Exchange Agreement (the "Warrant Exchange Agreement") with Ospraie Ag Science LLC ("Ospraie LLC"), Ardsley Partners Renewable Energy Fund, L.P., National Securities Corporation, Ivan Saval, Ivy Science & Technology Fund and Ivy VIP Science & Technology, pursuant to which Ospraie LLC exchanged all of the warrants to purchase Issuer Common Stock held by it for five tranches of new warrants ("New Warrants") to purchase Common Stock of the Issuer, totaling 21,736,082 New Warrants in the aggregate. Each New Warrant received by Ospraie LLC from the Issuer pursuant to the Warrant Exchange Agreement has an exercise price of $0.75 per share.

F2 · price: (Continued from footnote 1) Pursuant to the Warrant Exchange Agreement, Ospraie LLC agreed to exercise the first tranche of New Warrants on or before May 1, 2020. Ospraie LLC exercised such first tranche of New Warrants on May 1, 2020, and purchased 2,467,766 shares of Issuer Common Stock. The transactions pursuant to the Warrant Exchange Agreement were approved in advance by the Issuer's Board of Directors.

F3 · price: Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the general partner of Ospraie Holding.

F4 · price: (Continued from footnote 3) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and New Warrants held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F5 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement pursuant to which the Issuer had a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right was in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants (the "Reorganization Agreement Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such Reorganization Warrants were first exercisable 180 days after issuance, had a term expiring on January 1, 2023 and had an exercise price of $1.75 per share.

SEC source: 0000899243-20-007399 · doc4.xml · derivative · entry 3

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks)

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks)

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,027,325

Underlying: Common Stock · 5,027,325 shares

Expires 2023-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management.

F2 · kind: (Continued from Footnote 1) Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · kind: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants.

F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · price: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants.

F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · derivative.exercise_date: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants.

SEC source: 0000899243-20-007399 · doc4.xml · derivative · entry 2

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks)

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks)

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,233,158

Underlying: Common Stock · 5,027,325 shares

Expires 2021-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management.

F2 · kind: (Continued from Footnote 1) Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · kind: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants.

F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · price: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants.

F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · derivative.exercise_date: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants.

SEC source: 0000899243-20-007399 · doc4.xml · nonDerivative · entry 1

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks)

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks)

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,100,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management.

F2 · kind: (Continued from Footnote 1) Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding. Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · kind: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants.

F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · price: (Continued from Footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On March 4, 2020, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 5,027,325 warrants into shares of Common Stock and New Warrants.

SEC source: 0000899243-20-000043 · doc4.xml · derivative · entry 3

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks)

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks)

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,675,771

Underlying: Common Stock · 1,675,771 shares

Expires 2023-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F2 · kind: (Continued from Footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share.

F4 · kind: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants.

F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share.

F4 · price: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants.

F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share.

F4 · derivative.exercise_date: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants.

SEC source: 0000899243-20-000043 · doc4.xml · derivative · entry 2

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks)

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks)

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,260,483

Underlying: Common Stock · 1,675,771 shares

Expires 2021-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F2 · kind: (Continued from Footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share.

F4 · kind: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants.

F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share.

F4 · price: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants.

F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share.

F4 · derivative.exercise_date: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants.

SEC source: 0000899243-20-000043 · doc4.xml · nonDerivative · entry 1

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks)

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks)

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,072,851

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F2 · kind: (Continued from Footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share.

F4 · kind: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants.

F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised. Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share.

F4 · price: (Continued from Footnote 3) On December 30, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 1,675,771 warrants into shares of Common Stock and New Warrants.

SEC source: 0000899243-19-029736 · doc4.xml · derivative · entry 3

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks)

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks)

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,351,542

Underlying: Common Stock · 3,351,542 shares

Expires 2023-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F2 · kind: (Continued from footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · kind: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants

F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · price: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants

F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · derivative.exercise_date: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants

SEC source: 0000899243-19-029736 · doc4.xml · derivative · entry 2

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks)

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks)

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,936,254

Underlying: Common Stock · 3,351,542 shares

Expires 2021-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F2 · kind: (Continued from footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · kind: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants

F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · price: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants

F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · derivative.exercise_date: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants

SEC source: 0000899243-19-029736 · doc4.xml · nonDerivative · entry 1

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks)

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks)

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,397,080

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F2 · kind: (Continued from footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · kind: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants

F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's Common Stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · price: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On December 18, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised 3,351,542 warrants into shares of Common Stock and New Warrants

SEC source: 0000899243-19-022863 · doc4.xml · derivative · entry 3

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks)

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks)

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,378,871

Underlying: Common Stock · 8,378,871 shares

Expires 2023-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F2 · kind: (Continued from footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · kind: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants.

F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · price: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants.

F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · derivative.exercise_date: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants.

SEC source: 0000899243-19-022863 · doc4.xml · derivative · entry 2

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks)

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks)

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,287,796

Underlying: Common Stock · 8,378,871 shares

Expires 2021-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F2 · kind: (Continued from footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · kind: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants.

F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · price: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants.

F3 · derivative.exercise_date: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · derivative.exercise_date: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants.

SEC source: 0000899243-19-022863 · doc4.xml · nonDerivative · entry 1

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Ospraie Management, LLC · CIK 0001326533 · Director · 10% owner · (See Remarks)

Ospraie Holding I, L.P. · CIK 0001392205 · Director · 10% owner · (See Remarks)

Ospraie Management, Inc. · CIK 0001392203 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,045,538

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Ospraie Management, LLC ("Ospraie Management") is the investment manager of Ospraie LLC and has been delegated voting and investment power and thus beneficial ownership of the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC. Ospraie Holding I, LP ("Ospraie Holding") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the managing member of Ospraie Management. Ospraie Management, Inc. ("Ospraie Inc.") may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the general partner of Ospraie Holding.

F2 · kind: (Continued from footnote 1) Dwight Anderson may be deemed to beneficially own the shares of Common Stock of the Issuer and warrants to purchase shares of Common Stock of the Issuer held by Ospraie LLC as the Managing Principal of Ospraie Management, the sole owner of Ospraie Inc. and the sole managing member of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F3 · kind: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · kind: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants.

F3 · price: As previously disclosed, on August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the Issuer has a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of Common Stock underlying such warrants and new warrants ("New Warrants") to purchase shares of Common Stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F4 · price: (Continued from footnote 3) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. On September 4, 2019, following receipt of notice from the Issuer that the Issuer was exercising its right pursuant to the Agreement to require Ospraie LLC to exercise a portion of its warrants in exchange for shares of Common Stock of the Issuer and New Warrants, Ospraie LLC exercised the 8,378,871 warrants covered by the Issuer's notice into shares of Common Stock and New Warrants.

SEC source: 0000899243-19-021377 · doc4.xml · derivative · entry 2

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,666,667

Underlying: Common Stock · 30,666,667 shares

Expires 2021-12-31

F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Mr. Dwight Anderson ("Mr. Anderson") is the Managing Member of Ospraie LLC and, in such capacity, may be deemed to have voting and dispositive power over the securities held for the account of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F2 · kind: On August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the expiration date of the warrants to purchase common stock of the Issuer held by Ospraie LLC was extended to December 31, 2021. In addition, pursuant to the Agreement, the Issuer will have a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of common stock underlying such warrants and new warrants ("New Warrants") to purchase shares of common stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F3 · kind: (Continued from footnote 2) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. The transactions reported herein were approved in advance by the Issuer's Board of Directors.

F2 · price: On August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the expiration date of the warrants to purchase common stock of the Issuer held by Ospraie LLC was extended to December 31, 2021. In addition, pursuant to the Agreement, the Issuer will have a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of common stock underlying such warrants and new warrants ("New Warrants") to purchase shares of common stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F3 · price: (Continued from footnote 2) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. The transactions reported herein were approved in advance by the Issuer's Board of Directors.

F2 · derivative.exercise_date: On August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the expiration date of the warrants to purchase common stock of the Issuer held by Ospraie LLC was extended to December 31, 2021. In addition, pursuant to the Agreement, the Issuer will have a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of common stock underlying such warrants and new warrants ("New Warrants") to purchase shares of common stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F3 · derivative.exercise_date: (Continued from footnote 2) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. The transactions reported herein were approved in advance by the Issuer's Board of Directors.

SEC source: 0000899243-19-021377 · doc4.xml · derivative · entry 1

Ospraie Ag Science LLC · CIK 0001730557 · Director · 10% owner · (See Remarks)

Anderson Dwight · CIK 0001392202 · Director · 10% owner · (See Remarks)

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,666,667 shares

Expires 2020-12-31

F1 · kind: These securities of Marrone Bio Innovations, Inc. (the "Issuer") are or were held by Ospraie Ag Science LLC ("Ospraie LLC"). Mr. Dwight Anderson ("Mr. Anderson") is the Managing Member of Ospraie LLC and, in such capacity, may be deemed to have voting and dispositive power over the securities held for the account of Ospraie LLC. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any.

F2 · kind: On August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the expiration date of the warrants to purchase common stock of the Issuer held by Ospraie LLC was extended to December 31, 2021. In addition, pursuant to the Agreement, the Issuer will have a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of common stock underlying such warrants and new warrants ("New Warrants") to purchase shares of common stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F3 · kind: (Continued from footnote 2) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. The transactions reported herein were approved in advance by the Issuer's Board of Directors.

F2 · price: On August 6, 2019, the Issuer, Ospraie LLC, Ardsley Partners Renewable Energy Fund, L.P. and Ivan Saval entered into a Warrant Amendment and Plan of Reorganization Agreement (the "Agreement") pursuant to which the expiration date of the warrants to purchase common stock of the Issuer held by Ospraie LLC was extended to December 31, 2021. In addition, pursuant to the Agreement, the Issuer will have a right, so long as the closing price for the Issuer's common stock on its principal market immediately prior to the exercise of such right is in excess of the exercise price for the warrants, to require Ospraie LLC to exercise up to all of its warrants in exchange for the shares of common stock underlying such warrants and new warrants ("New Warrants") to purchase shares of common stock of the Issuer in an amount equal to the amount of warrants being required to be exercised.

F3 · price: (Continued from footnote 2) Such New Warrants will be first exercisable 180 days after issuance, will have a term expiring on January 1, 2023 and will have an exercise price of $1.75 per share. The transactions reported herein were approved in advance by the Issuer's Board of Directors.